HLA-DRB1 and myopathy: In light of these considerations, the present study aimed to evaluate whether genetic variants in SLCO1B1 and the HLA-DRB1*11 allele can be predictive biomarkers to identify patients at elevated risk for severe myopathy, thereby informing clinical decision-making to avoid statin use in susceptible individuals and guiding optimal therapeutic strategies.